Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients With B7-H3-Expressing Relapsed or Refractory Solid Tumors

NCT02982941 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT02982941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02982941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients With B7-H3-Expressing Relapsed or Refractory Solid Tumors
Lead sponsor
MacroGenics
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2016
Completion date
May 22, 2019
Enrollment
25 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

desmoplastic small round cell tumor, ewing sarcoma, neuroblastoma, osteosarcoma, rhabdomyosarcoma, wilms tumor